{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:00:19Z","timestamp":1772827219715,"version":"3.50.1"},"reference-count":59,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2018,5]]},"abstract":"\n Aim:<\/jats:bold>\n A systematic literature review and network meta-analysis were conducted to determine the relative efficacy and safety of interventions for treatment-naive chronic lymphocytic leukemia patients, as comparative evidence is scarce.\n Materials & methods:<\/jats:bold>\n Relative treatment effects of progression-free survival, overall survival and safety outcomes were estimated via network meta-analysis based on data identified via systematic literature review.\n Results:<\/jats:bold>\n Ibrutinib was superior in all pairwise comparisons for progression-free survival (probability to be better [P] range: overall population:\u00a069\u2013100%; fludarabine-ineligible population: 69\u2013100%) and overall survival (P range: overall: 89\u2013100%; fludarabine-ineligible: 91\u2013100%) and had the highest probability of being best for all outcomes.\n Conclusion:<\/jats:bold>\n Ibrutinib provides superior benefit in survival and safety compared with other front-line treatments of chronic lymphocytic leukemia.\n <\/jats:p>","DOI":"10.2217\/cer-2017-0086","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T14:34:59Z","timestamp":1512570899000},"page":"421-441","source":"Crossref","is-referenced-by-count":8,"title":["Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis"],"prefix":"10.57264","volume":"7","author":[{"given":"Yingxin","family":"Xu","sequence":"first","affiliation":[{"name":"Evidera, Waltham, MA, 02451 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Fahrbach","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, MA, 02451 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Dorman","sequence":"additional","affiliation":[{"name":"Evidera, Bethesda, MD, 20814 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Baculea","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd, High Wycombe, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd, High Wycombe, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzy van","family":"Sanden","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"5","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"V78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst B","year":"2015","unstructured":"Eichhorst B , Robak T , Montserrat E Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up . Ann. Oncol. 26 ( Suppl. 5 ), V78 \u2013 V84 ( 2015 ). www.esmo.org\/Guidelines\/Haematological-Malignancies\/Chronic-Lymphocytic-Leukaemia\/eUpdate-Treatment-Recommendations .","journal-title":"Ann. Oncol."},{"key":"e_1_3_4_4_2","unstructured":"American Cancer Society\n . \n Cancer Facts & Figures 2017\n . \n American Cancer Society GA USA\n (\n 2017\n ). \n www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2017.html\n ."},{"issue":"3","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd JC","year":"2014","unstructured":"Byrd JC , Brown JR , O'brien S Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia . N. Engl. J. Med. 371 ( 3 ), 213 \u2013 223 ( 2014 ).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts AW","year":"2016","unstructured":"Roberts AW , Davids MS , Pagel JM Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia . N. Engl. J. Med. 374 ( 4 ), 311 \u2013 322 ( 2016 ).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_4_7_2","unstructured":"National Comprehensive Cancer Network\n . \n NCCN Clinical Practice Guidelines in Oncology: chronic lymphocytic leukemia\/small lymphocytic lymphoma\n . \n Version 1.2017\n (\n 2016\n ). \n www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf\n ."},{"issue":"1","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug N","year":"2014","unstructured":"Pflug N , Bahlo J , Shanafelt TD Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia . Blood 124 ( 1 ), 49 \u2013 62 ( 2014 ).","journal-title":"Blood"},{"issue":"8","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3109\/10428194.2011.568654","article-title":"Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach","volume":"52","author":"Zent CS","year":"2011","unstructured":"Zent CS , Kay NE . Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach . Leuk. Lymphoma 52 ( 8 ), 1425 \u2013 1434 ( 2011 ).","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s12325-017-0564-1","article-title":"Comparative efficacy of ibrutinib versus obinutuzumab + chlorambucil in first line treatment of chronic lymphocytic leukemia: a matching-adjusted indirect comparison","volume":"34","author":"Van Sanden S","year":"2017","unstructured":"Van Sanden S , Baculea S , Diels J , Cote S . Comparative efficacy of ibrutinib versus obinutuzumab + chlorambucil in first line treatment of chronic lymphocytic leukemia: a matching-adjusted indirect comparison . Adv. Ther. 34 ( 7 ), 1650 \u2013 1661 ( 2017 ).","journal-title":"Adv. Ther."},{"issue":"7","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, Phase III, non-inferiority trial","volume":"17","author":"Eichhorst B","year":"2016","unstructured":"Eichhorst B , Fink AM , Bahlo J First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, Phase III, non-inferiority trial . Lancet Oncol. 17 ( 7 ), 928 \u2013 942 ( 2016 ).","journal-title":"Lancet Oncol."},{"issue":"7521","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell DM","year":"2005","unstructured":"Caldwell DM , Ades AE , Higgins JP . Simultaneous comparison of multiple treatments: combining direct and indirect evidence . BMJ 331 ( 7521 ), 897 \u2013 900 ( 2005 ).","journal-title":"BMJ"},{"issue":"20","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu G","year":"2004","unstructured":"Lu G , Ades AE . Combination of direct and indirect evidence in mixed treatment comparisons . Stat. Med. 23 ( 20 ), 3105 \u2013 3124 ( 2004 ).","journal-title":"Stat. Med."},{"issue":"12","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede V","year":"2014","unstructured":"Goede V , Fischer K , Busch R Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions . N. Engl. J. Med. 370 ( 12 ), 1101 \u2013 1110 ( 2014 ).","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger JA","year":"2015","unstructured":"Burger JA , Tedeschi A , Barr PM Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia . N. Engl. J. Med. 373 ( 25 ), 2425 \u2013 2437 ( 2015 ).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_4_16_2","volume-title":"XVI International Workshop on Chronic Lymphocytic Leukaemia","author":"Michallet AS","year":"2015","unstructured":"Michallet AS . Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised Phase IIIb MABLE study . Presented at : XVI International Workshop on Chronic Lymphocytic Leukaemia . Sydney, Australia , 7\u20139 September, 2015 ."},{"issue":"9583","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky D","year":"2007","unstructured":"Catovsky D , Richards S , Matutes E Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial . Lancet 370 ( 9583 ), 230 \u2013 239 ( 2007 ).","journal-title":"Lancet"},{"issue":"24","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai KR","year":"2000","unstructured":"Rai KR , Peterson BL , Appelbaum FR Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia . N. Engl. J. Med. 343 ( 24 ), 1750 \u2013 1757 ( 2000 ).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3109\/10428194.2014.893306","article-title":"Cladribine prolongs progression-free survival and time to second treatment compared with fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia","volume":"55","author":"Mulligan SP","year":"2014","unstructured":"Mulligan SP , Karlsson K , Stromberg M Cladribine prolongs progression-free survival and time to second treatment compared with fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia . Leuk. Lymphoma 55 ( 12 ), 2769 \u2013 2777 ( 2014 ).","journal-title":"Leuk. Lymphoma"},{"issue":"16","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst BF","year":"2009","unstructured":"Eichhorst BF , Busch R , Stilgenbauer S First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia . Blood 114 ( 16 ), 3382 \u2013 3391 ( 2009 ).","journal-title":"Blood"},{"issue":"9980","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label Phase III trial","volume":"385","author":"Hillmen P","year":"2015","unstructured":"Hillmen P , Robak T , Janssens A Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label Phase III trial . Lancet 385 ( 9980 ), 1873 \u2013 1883 ( 2015 ).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_4_22_2","first-page":"114","article-title":"Obinutuzumab (GA101) + chlorambucil (CLB) or rituximab (R) + CLB versus CLB alone in patients with chronic lymphocytic leukaemia (CLL) and pre-existing medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) Phase III trial","volume":"31","author":"Hallek M","year":"2013","unstructured":"Hallek M , Fischer K , Humphrey K Obinutuzumab (GA101) + chlorambucil (CLB) or rituximab (R) + CLB versus CLB alone in patients with chronic lymphocytic leukaemia (CLL) and pre-existing medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) Phase III trial . Hematol. Oncol. 31 ( Suppl. 1 ), 114 ( 2013 ).","journal-title":"Hematol. Oncol."},{"issue":"21","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V122.21.6.6","article-title":"Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): final stage 2 results of the CLL11 trial. Presented at: The 55th American Society of Hematology (ASH) Annual Meeting and Exposition. LA, USA, 7\u201310 December","volume":"122","author":"Goede V","year":"2013","unstructured":"Goede V , Fischer K , Busch R Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): final stage 2 results of the CLL11 trial. Presented at: The 55th American Society of Hematology (ASH) Annual Meeting and Exposition. LA, USA, 7\u201310 December . Blood 122 ( 21 ), 6 ( 2013 ).","journal-title":"Blood"},{"key":"e_1_3_4_24_2","volume-title":"ASCO Annual Meeting 2013","author":"Goede V","year":"2013","unstructured":"Goede V , Fischer K , Humphrey K Obinutuzumab (GA101) + chlorambucil (CLB) or rituximab (R) + CLB versus CLB alone in patients with chronic lymphocytic leukaemia (CLL) and pre-existing medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) Phase III trial . Presented at : ASCO Annual Meeting 2013 . IL, USA , 31 May\u20134 June 2013 ."},{"issue":"1","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","article-title":"Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized Phase III trial","volume":"159","author":"Knauf WU","year":"2012","unstructured":"Knauf WU , Lissitchkov T , Aldaoud A Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized Phase III trial . Br. J. Haematol. 159 ( 1 ), 67 \u2013 77 ( 2012 ).","journal-title":"Br. J. Haematol."},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2043.2043","article-title":"Bendamustine versus chlorambucil in treatment-naive patients with B cell chronic lymphocytic leukemia (B-CLL): results of an international Phase III study","volume":"110","author":"Knauf WU","year":"2007","unstructured":"Knauf WU , Lissitchkov T , Aldaoud A Bendamustine versus chlorambucil in treatment-naive patients with B cell chronic lymphocytic leukemia (B-CLL): results of an international Phase III study . Blood 110 , Abstract 2043 ( 2007 ).","journal-title":"Blood"},{"issue":"26","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf WU","year":"2009","unstructured":"Knauf WU , Lissichkov T , Aldaoud A Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia . J. Clin. Oncol. 27 ( 26 ), 4378 \u2013 4384 ( 2009 ).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.630.630","article-title":"Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from the international randomized Phase III trial","volume":"110","author":"Karlsson K","year":"2007","unstructured":"Karlsson K , Stromberg M , Jonsson V , Mulligan SP , Liliemark J , Juliusson G . Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from the international randomized Phase III trial . Blood 110 , Abstract 630 ( 2007 ).","journal-title":"Blood"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.3470.3470","article-title":"Cladribine (CdA) or fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia? First interim analysis of data from the international randomized Phase III trial","volume":"104","author":"Karlsson K","year":"2004","unstructured":"Karlsson K , Stromberg M , Jonsson V Cladribine (CdA) or fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia? First interim analysis of data from the international randomized Phase III trial . Blood 104 , Abstract 3470 ( 2004 ).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst BF","year":"2006","unstructured":"Eichhorst BF , Busch R , Hopfinger G Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia . Blood 107 ( 3 ), 885 \u2013 891 ( 2006 ).","journal-title":"Blood"},{"issue":"5","key":"e_1_3_4_31_2","first-page":"V89","article-title":"Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of younger patients (Pts) with chronic lymphocytic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG)","volume":"16","author":"Eichhorst B","year":"2005","unstructured":"Eichhorst B , Busch R , Emmerich B , Hallek M Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of younger patients (Pts) with chronic lymphocytic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG) . Ann. Oncol. 16 ( Suppl. 5 ), V89 \u2013 V90 ( 2005 ).","journal-title":"Ann. Oncol."},{"issue":"2","key":"e_1_3_4_32_2","first-page":"144","article-title":"Fludarabine plus cyclophosphamide (FC) is superior to fludarabine (F) alone in first line therapy of chronic lymphoblastic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG)","volume":"90","author":"Eichhorst B","year":"2005","unstructured":"Eichhorst B , Busch R , Hopfinger G Fludarabine plus cyclophosphamide (FC) is superior to fludarabine (F) alone in first line therapy of chronic lymphoblastic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG) . Haematologica 90 ( S2 ), 144 ( 2005 ).","journal-title":"Haematologica"},{"issue":"11","key":"e_1_3_4_33_2","first-page":"72a","article-title":"Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): results of a Phase III study (CLL4 protocol)","volume":"102","author":"Eichhorst B","year":"2003","unstructured":"Eichhorst B , Busch R , Hopfinger G Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): results of a Phase III study (CLL4 protocol) . Blood 102 ( 11 ), 72a ( 2003 ).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2141.2006.06382.x","article-title":"Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy","volume":"136","author":"Eichhorst BF","year":"2007","unstructured":"Eichhorst BF , Busch R , Schweighofer C Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy . Br. J. Haematol. 136 ( 1 ), 63 \u2013 72 ( 2007 ).","journal-title":"Br. J. Haematol."},{"issue":"7","key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn IW","year":"2007","unstructured":"Flinn IW , Neuberg DS , Grever MR Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997 . J. Clin. Oncol. 25 ( 7 ), 793 \u2013 798 ( 2007 ).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997","volume":"25","author":"Grever MR","year":"2007","unstructured":"Grever MR , Lucas DM , Dewald GW Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 . J. Clin. Oncol. 25 ( 7 ), 799 \u2013 804 ( 2007 ).","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011","volume":"19","author":"Morrison VA","year":"2001","unstructured":"Morrison VA , Rai KR , Peterson BL Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011 . J. Clin. Oncol. 19 ( 16 ), 3611 \u2013 3621 ( 2001 ).","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2011.41.0852","article-title":"Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom leukemia research fund chronic lymphocytic leukemia 4 trial","volume":"30","author":"Skowronska A","year":"2012","unstructured":"Skowronska A , Parker A , Ahmed G Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom leukemia research fund chronic lymphocytic leukemia 4 trial . J. Clin. Oncol. 30 ( 36 ), 4524 \u2013 4532 ( 2012 ).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/cncr.25776","article-title":"A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial","volume":"117","author":"Dearden CE","year":"2011","unstructured":"Dearden CE , Richards S , Else M , Catovsky D , Hillmen P . A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial . Cancer 117 ( 11 ), 2452 \u2013 2460 ( 2011 ).","journal-title":"Cancer"},{"issue":"8","key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3109\/10428194.2013.796050","article-title":"Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group","volume":"54","author":"Cramer P","year":"2013","unstructured":"Cramer P , Fink AM , Busch R Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group . Leuk. Lymphoma 54 ( 8 ), 1821 \u2013 1822 ( 2013 ).","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40273-013-0125-7","article-title":"Modelling the cost\u2013effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse","volume":"32","author":"Adena M","year":"2014","unstructured":"Adena M , Houltram J , Mulligan SP , Todd C , Malanos G . Modelling the cost\u2013effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse . Pharmacoeconomics 32 ( 2 ), 193 \u2013 207 ( 2014 ).","journal-title":"Pharmacoeconomics"},{"issue":"9747","key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase III trial","volume":"376","author":"Hallek M","year":"2010","unstructured":"Hallek M , Fischer K , Fingerle-Rowson G Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase III trial . Lancet 376 ( 9747 ), 1164 \u2013 1174 ( 2010 ).","journal-title":"Lancet"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","unstructured":"Main\n C Pitt\n M Moxham\n T Stein\n K\n . \n The clinical and cost\u2013effectiveness of rituximab for the 1st line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche\n . \n Produced by the Peninsula Technology Assessment Group (Pentag) on behalf of the National Institute of Health and Care Excellence (NICE). NICE London\n (\n 2009\n ). \n www.nice.org.uk\/guidance\/ta174\/documents\/leukaemia-chronic-lymphocytic-first-line-rituximab-evidence-review-group-report2\n .","DOI":"10.3310\/hta14suppl2-04"},{"key":"e_1_3_4_44_2","volume-title":"50th ASH Annual Meeting and Exposition","author":"Hallek M","year":"2008","unstructured":"Hallek M , Fingerle-Rowson G , Fink AM Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) . Presented at : 50th ASH Annual Meeting and Exposition . CA, USA , 6\u20139 December, 2008 ."},{"issue":"21","key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer S","year":"2014","unstructured":"Stilgenbauer S , Schnaiter A , Paschka P Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial . Blood 123 ( 21 ), 3247 \u2013 3254 ( 2014 ).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_4_46_2","first-page":"132","article-title":"First line therapy of elderly patients with chronic lymphocytic leukaemia (CLL) \u2013 long term follow-up (FU) results of a randomized Phase III study of the German CLL Study Group (CLL5 study of the GCLLSG). Oral presentation (Abstract 107) presented at: 12th International Conference on Malignant Lymphoma. Lugano, Switzerland, 19\u201322 June 2013","volume":"31","author":"Eichhorst B","year":"2013","unstructured":"Eichhorst B , Bahlo J , Stauch M First line therapy of elderly patients with chronic lymphocytic leukaemia (CLL) \u2013 long term follow-up (FU) results of a randomized Phase III study of the German CLL Study Group (CLL5 study of the GCLLSG). Oral presentation (Abstract 107) presented at: 12th International Conference on Malignant Lymphoma. Lugano, Switzerland, 19\u201322 June 2013 . Hematol. Oncol. 31 ( Suppl. 1 ), 132 ( 2013 ).","journal-title":"Hematol. Oncol."},{"issue":"3","key":"e_1_3_4_47_2","first-page":"O145","article-title":"Fludarabine (F) induces higher response rates and longer event free survival in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a Phase Ill study of the German CLL Study Group (GCLLSG)","volume":"27","author":"Eichhorst B","year":"2004","unstructured":"Eichhorst B , Busch R , Stauch M Fludarabine (F) induces higher response rates and longer event free survival in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a Phase Ill study of the German CLL Study Group (GCLLSG) . Onkologie 27 ( Suppl. 3 ), O145 ( 2004 ).","journal-title":"Onkologie"},{"issue":"11","key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.V110.11.629.629","article-title":"No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients (Pts) with advanced chronic lymphocytic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG)","volume":"110","author":"Eichhorst B","year":"2007","unstructured":"Eichhorst B , Busch R , Stauch M No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients (Pts) with advanced chronic lymphocytic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG) . Blood 110 ( 11 ), 629 ( 2007 ).","journal-title":"Blood"},{"issue":"4","key":"e_1_3_4_49_2","first-page":"170","article-title":"First line therapy with fludarabine versus chlorambucil for patients with advanced chronic lymphocytic leukemia (CLL) older than 65 years: first interim analysis of a Phase Ill study (CLL5 protocol) of the German CLL Study Group (GCLLSG)","volume":"25","author":"Schmitt B","year":"2002","unstructured":"Schmitt B , Kneba M , Ritgen M First line therapy with fludarabine versus chlorambucil for patients with advanced chronic lymphocytic leukemia (CLL) older than 65 years: first interim analysis of a Phase Ill study (CLL5 protocol) of the German CLL Study Group (GCLLSG) . Onkologie 25 ( 4 ), 170 ( 2002 ).","journal-title":"Onkologie"},{"issue":"11","key":"e_1_3_4_50_2","first-page":"109a","article-title":"Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a Phase III study of the German CLL Study Group (GCLLSG)","volume":"102","author":"Eichhorst B","year":"2003","unstructured":"Eichhorst B , Busch R , Stauch M Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a Phase III study of the German CLL Study Group (GCLLSG) . Blood 102 ( 11 ), 109a ( 2003 ).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_4_51_2","first-page":"97","article-title":"Fludarabine versus high-dose continuous chlorambucil in untreated patients with B-CLL: results of CLL1 EORTC randomized trial","volume":"42","author":"Jaksic B","year":"2000","unstructured":"Jaksic B , Brugiatelli M , Suciu S Fludarabine versus high-dose continuous chlorambucil in untreated patients with B-CLL: results of CLL1 EORTC randomized trial . Hematol. Cell Ther. 42 ( 1 ), 97 ( 2000 ).","journal-title":"Hematol. Cell Ther."},{"issue":"10","key":"e_1_3_4_52_2","first-page":"588a","article-title":"Fludarabine vs. high dose continuous chlorambucil: interim analysis of a randomized Phase II study in untreated B-cell chronic lymphocytic leukemia (B-CLL)","volume":"88","author":"Jaksic B","year":"1996","unstructured":"Jaksic B , Delmer A , Brugiatelli M Fludarabine vs. high dose continuous chlorambucil: interim analysis of a randomized Phase II study in untreated B-cell chronic lymphocytic leukemia (B-CLL) . Blood 88 ( 10 Suppl. 1 ), 588a ( 1996 ).","journal-title":"Blood"},{"issue":"10","key":"e_1_3_4_53_2","first-page":"103a","article-title":"Randomized Phase II study in untreated B-cell chronic lymphocytic leukemia (B:CLL) comparing fludarabine (FAMP) vs. high dose continuous chlorambucil (HD-CLB)","volume":"92","author":"Jaksic B","year":"1998","unstructured":"Jaksic B , Brugiatelli M , Suciu S Randomized Phase II study in untreated B-cell chronic lymphocytic leukemia (B:CLL) comparing fludarabine (FAMP) vs. high dose continuous chlorambucil (HD-CLB) . Blood 92 ( 10 Suppl. 1 ), 103a ( 1998 ).","journal-title":"Blood"},{"issue":"21","key":"e_1_3_4_54_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood.V122.21.526.526","article-title":"Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL study group (GCLLSG). Abstract presented at: 55th American Society of Hematology Annual Meeting and Exposition. LA, USA, 7\u201313 December 2013","volume":"122","author":"Eichhorst B","year":"2013","unstructured":"Eichhorst B , Fink AM , Busch R Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL study group (GCLLSG). Abstract presented at: 55th American Society of Hematology Annual Meeting and Exposition. LA, USA, 7\u201313 December 2013 . Blood 122 ( 21 ), 526 ( 2013 ).","journal-title":"Blood"},{"key":"e_1_3_4_55_2","unstructured":"Langerbeins\n P Busch\n R Schweighofer\n C\n Severe infections are more common in physically fit CLL patients with FCR-therapy compared to BR: results of the intermin-analysis of the CLL10 trial of the German Cll Study Group\n . \n www.newevidence.com\/oncology\/wp-content\/uploads\/2015\/07\/journal-201409.pdf\n ."},{"issue":"21","key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V124.21.19.19","article-title":"Frontline chemoimmunotherapy with fludarabin (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international randomized study of the German CLL Study Group (GCLLSG) (CLL10 study)","volume":"124","author":"Eichhorst B","year":"2014","unstructured":"Eichhorst B , Fink AM , Busch R Frontline chemoimmunotherapy with fludarabin (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international randomized study of the German CLL Study Group (GCLLSG) (CLL10 study) . Blood 124 ( 21 ), 19 ( 2014 ).","journal-title":"Blood"},{"issue":"10","key":"e_1_3_4_57_2","first-page":"141a","article-title":"A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG\/NCI-C and ECOG inter-group study","volume":"88","author":"Rai KR","year":"1996","unstructured":"Rai KR , Peterson B , Elias L A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG\/NCI-C and ECOG inter-group study . Blood 88 ( Suppl. 10 ), 141a ( 1996 ).","journal-title":"Blood"},{"issue":"10","key":"e_1_3_4_58_2","article-title":"Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). A randomized inter-group study","volume":"86","author":"Rai KR","year":"1995","unstructured":"Rai KR , Peterson B , Kolitz J Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). A randomized inter-group study . Blood 86 ( 10 Suppl. 1 ), Abstract 2414 ( 1995 ).","journal-title":"Blood"},{"issue":"22","key":"e_1_3_4_59_2","first-page":"234","article-title":"Updated efficacy and safety from the Phase III RESONATE-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia\/small lymphocytic leukemia. Abstract presented at: American Society of Hematology 58th Annual Meeting & Exposition, CA, USA, 3\u20136 December 2016","volume":"128","author":"Barr PM","year":"2016","unstructured":"Barr PM , Robak T , Owen CJ Updated efficacy and safety from the Phase III RESONATE-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia\/small lymphocytic leukemia. Abstract presented at: American Society of Hematology 58th Annual Meeting & Exposition, CA, USA, 3\u20136 December 2016 . Blood 128 ( 22 ), 234 ( 2016 ).","journal-title":"Blood"},{"key":"e_1_3_4_60_2","volume-title":"19th Congress of the European Hematology Association","author":"Rancea M","year":"2014","unstructured":"Rancea M , Skoetz N , Trelle S First-line treatment strategies for previously untreated patients with chronic lymphocytic leukaemia: preliminary results of a network meta-analysis . Presented at : 19th Congress of the European Hematology Association . Milan, Italy , 12\u201315 June 2014 ."},{"issue":"10","key":"e_1_3_4_61_2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s12325-016-0398-2","article-title":"A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia","volume":"33","author":"Stadler N","year":"2016","unstructured":"Stadler N , Shang A , Bosch F A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia . Adv. Ther. 33 ( 10 ), 1814 \u2013 1830 ( 2016 ).","journal-title":"Adv. Ther."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2017-0086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:17:58Z","timestamp":1679231878000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2017-0086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.2217\/cer-2017-0086"],"URL":"https:\/\/doi.org\/10.2217\/cer-2017-0086","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}